Mitapivat Matched Placebo

DRUG2 trials

Sponsors

Agios Pharmaceuticals, Inc.

Conditions

Sickle Cell DiseaseTransfusion-dependent Alpha-ThalassemiaTransfusion-dependent Beta-Thalassemia

Phase 3

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

RecruitingNCT07506863

Agios Pharmaceuticals, Inc.Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia

Start: 2026-09-01End: 2032-06-01Target: 54Updated: 2026-08-27

A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

RecruitingNCT07656415

Agios Pharmaceuticals, Inc.Sickle Cell Disease

Start: 2026-07-21End: 2030-08-01Target: 159Updated: 2026-08-04